Forget BMS. Pfizer should chase a Biogen buy, analyst suggests

13th November 2017 Uncategorised 0

One analyst isn’t sure Pfizer can afford to be behind in both immuno-oncology and Alzheimer’s. And while his peers have suggested bulking up in I-O to solve that issue, he has a different idea.

More: Forget BMS. Pfizer should chase a Biogen buy, analyst suggests
Source: fierce